Seroprevalence of Hepatitis E among Iranian Renal Transplant Recipients

AUTHORS

Zakieh Rostamzadeh Khameneh 1 , Nariman Sepehrvand 2 , * , Sima Masudi 3

1 Department of Microbiology and Immunology, Urmia University of Medical Sciences, IR Iran

2 Students Research Committee, Deputy for Research Affairs, Urmia University of Medical Sciences, [email protected], IR Iran

3 Deputy for Research Affairs, Shahid Beheshti University of Medical Sciences, IR Iran

How to Cite: Rostamzadeh Khameneh Z, Sepehrvand N, Masudi S. Seroprevalence of Hepatitis E among Iranian Renal Transplant Recipients, Hepat Mon. Online ahead of Print ; 11(8):646-651. doi: 10.5812/kowsar.1735143X.690.

ARTICLE INFORMATION

Hepatitis Monthly: 11 (8); 646-651
Article Type: Research Article
Received: November 16, 2010
Accepted: April 16, 2011
Crossmark

Crossmark

CHEKING

READ FULL TEXT
Abstract

Background: Renal transplant recipients are known to be susceptible to viral infections, with more severe clinical presentations compared to healthy persons. Hepatitis E is generally a self-limited disease, which is caused by hepatitis E virus. Recently, hepatitis E has become more important in organ transplant recipients, because of new findings regarding the potential for chronic infections in this patient group.
Objectives: This study aimed to evaluate the seroprevalence of anti-HEV IgG among kidney transplant recipients in Urmia, in the north-western region of Iran.
Patients and Methods: 91 patients were selected randomly from amongst patients who had undergone kidney transplantation in Urmia, Iran. Each patient was tested for the presence of anti-HEV IgG antibody using an enzyme-linked immunosorbent assay (ELISA, Dia.Pro; Diagnostic Bioprobes, Italy).
Results: 28 subjects (30.8%) were seropositive for anti-HEV IgG. Seropositive patients were generally older than seronegative patients (P = 0.009). There was no correlation between HEV infection and the level of education (P = 0.206), the history of blood transfusion (P = 0.164), or history of pre-transplantation hemodialysis (P = 0.228). There was no significant difference in the serum alanine aminotransferase (ALT) levels of the anti-HEV seropositive and seronegative patients. Multinomial logistic regression analysis indicated no significant relationship between HEV infection and increase in ALT levels, even after controlling for treatment with azathioprine (P = 0.79, OR = 1.12; 95% CI: 0.45-2.76).
Conclusion: The anti-HEV IgG antibody has a high prevalence in Iranian kidney transplant recipients, and it is significantly higher in comparison with previous studies in the general population or in hemodialysis patients. 


 

  • Implication for health policy/practice/research/medical education:
    The prevalence rate of anti-HEV IgG in transplant recipients is independent of its prevalence in the general population. In the setting of transplant recipients, the clinicians should not look merely for clinical evidence to consider hepatitis E.
  • Please cite this paper as:
    Khameneh ZR, Sepehrvand N, Masudi S. Seroprevalence of Hepatitis E among Iranian Renal Transplant Recipients. Hepat Mon. 2011;11(8):646-51. [DOI: 10.5812/kowsar.1735143X.690]

 © 2011 Kowsar M.P.Co. All rights reserved.

 


Keywords

Hepatitis E ELISA Anti-HEV IgG Renal transplantation

© 0, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Full Text

Full text is available in PDF

COMMENTS

LEAVE A COMMENT HERE: